Edwin Southern, DNA blotting, and microarray technology: A case study of the shifting role of patents in academic molecular biology by Daidree Tofano et al.
            Genomics, Society and Policy 
            2006, Vol.2, No.2, pp.50-61 
 
_____________  50 
 
Genomics, Society and Policy, Vol.2 No.2 (2006) ISSN: 1746-5354 
Edwin Southern, DNA blotting, and microarray technology: A case 
study of the shifting role of patents in academic molecular biology 
 




Edwin Southern developed a blotting technique for DNA in 1973, thereby creating a 
staple of molecular biology laboratory procedures still used after several decades. It 
became a seminal technology for studying the structure of DNA. The story of the 
creation and dissemination of this technology, which was not patented and was freely 
distributed throughout the scientific community, stands as a case study in open 
science. The Southern blot was developed at a time when attitudes about commercial 
intrusion into health research were beginning to change and the practical value of 
molecular genetics was becoming apparent to industry. Interest from industry in 
fundamental molecular biological techniques meant that scientists began to think 
about commercial uses of their work even in otherwise “basic” research. The 
unpatented Southern blot is contrasted with later patented technologies, particularly 
microarray methods, which were created in the same environment by many of the 
same people, but which followed significant changes to UK policies encouraging 
commercialization of academic research and a norm shift friendlier to such 
commercialization within academic molecular biology. Professor Southern’s personal 
experience illuminates how the technologies evolved, and his views provide insight 
into how scientists’ attitudes about commercialization have changed. 

An Environment for Innovation 
 
Edwin Southern studied chemistry at University of Manchester and then went on to 
study nucleic acids, receiving his Ph.D. in biochemistry from the University of 
Glasgow in 1962. After working for four years at the Antarctic Research Centre Low 
Temperature Research Station in Cambridge, he joined the MRC Mammalian 
Genome Unit in Edinburgh in 1967. A pioneer institution in the field that would 
eventually be called genomics,2 the Mammalian Genome Unit’s staff consisted of 
several people who would later become leaders in the burgeoning field. Professor Sir 
Kenneth Murray was among the future genomics heavyweights whom Southern 
identifies as mentors. Murray co-discovered the Hepatitis B antigen and later co-
founded the biotechnology company Biogen, one of the early biotechnology start-up 
firms, and the first to span the Atlantic. 
 
A collegial environment within the Mammalian Genome Unit promoted innovation 
while allowing for a great deal of open sharing of scientific findings. According to 
Southern, competition rarely led to knowledge-hoarding, and information flowed 
relatively freely both within and between laboratories.3 To illustrate this open 
scientific culture, Southern cites the participation of his fellow scientists in a 
“restriction enzyme club,” active during his time at MRC: 
 
‘People were very keen to share. Just to give you one example, when 
restriction enzymes first came out… Ken Murray in Edinburgh set up 
a club to make restriction enzymes. To join the club, you had to 
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make one, and you had to share the one you made with everyone 
else. It was very much a culture of sharing. And, I think as far as 
technology is concerned, whenever anybody had a technique in their 




Competition among researchers certainly existed in the Unit; unfettered information-
sharing is a utopian ideal rarely realized in practice. A general culture of sharing 
nonetheless prevailed, and contributed to Southern’s success in innovation. Peter 
Walker’s lab, in particular, proved to be an excellent place for Southern to exploit his 
knack for inventiveness. Peter Walker, head of the Unit, was himself an innovator and 
promoted instrument development through a “creation workshop” in his lab.5 If a 
researcher working in Walker’s lab did not have the proper piece of equipment to 
complete an experiment, the researcher could go into the workshop and build the 
needed device. Walker’s lab thus married scientific inquiry to practical design and 
prototyping of instruments, and was poised for the development of innovative 
technology. 
 
Two crucial factors influenced Southern’s innovation process: “necessity…the mother 
of invention”6 and “laziness, the father.”7 Driving Southern’s development of the new 
blotting technology was the need to isolate the 5S ribosomal RNA (rRNA) genes, 
which he needed to study the transcription of ribosomal RNA from DNA. The usual 
method for purifying genes at that time, density gradient centrifugation, turned out to 
be inadequate for the task. Southern instead isolated these genes by cutting the DNA 
with restriction endonucleases and separating the fragments by size through gel 
electrophoresis. Having separated genes in a gel, Southern was then confronted with 
the dilemma of extracting these genes back out of the gel. As Southern stated, “the 
prospect of cutting lots of gels into hundreds of slices, eluting the DNA from each of 
them and binding this to a filter that would then be hybridized and counted drove me 
to think that there had to be a better way of doing it.”8 While searching for this “better 




The Southern blot is an ingenious synthesis of prior technologies and biological 
findings. A few years before the Southern blot was developed, Tom Kelly and 
Hamilton Smith, both at Johns Hopkins University, had shown that restriction 
endonucleases cut at specific sequence sites along DNA.9 Kenneth and Noreen 
Murray introduced Southern to these restriction endonucleases. In 1971, Kathleen 
Danna and Daniel Nathans, also of Johns Hopkins, showed how gel electrophoresis 
could separate DNA fragments.10 Southern credits Frederick Sanger’s work with 
bringing to his attention “the notion of transferring DNA fragments from one medium 
to another.”11 Sanger’s method separated RNA fragments on cellulose acetate strips 
via electrophoresis and transferred the molecules to DEAE paper by “blotting 
through.”12 Southern integrated these three innovations—restriction endonucleases, 
gel electrophoresis, and blotting-through methods—to create the Southern blot. 
 
The Southern blot process works as follows: DNA to be analyzed is digested into 
small pieces by restriction enzymes.13 The millions of resulting DNA fragments then 
undergo gel electrophoresis, which separates the fragments according to size. Once 
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the DNA is separated in the gel, the gel is placed on filter paper, where capillary 
action transfers the alkali-denatured DNA fragments from the gel to a nitrocellulose 
filter (as originally used by Southern) or nylon membrane (adopted later)—the 
“blotting” step. Once bound and immobilized on a surface medium rather than 
embedded in a gel, the DNA can easily be incubated under hybridization conditions 
with labeled DNA probes. These probes can be detected by radioactivity, 
fluorescence, or other methods, allowing for the visualization of the DNA fragments 
that are bound to the probes. 
 
As soon as the Southern blot idea was explained, its utility was both obvious and 
extensive. Nearly every molecular biology laboratory engaged in DNA studies had to 
separate DNA fragments, and the Southern blot greatly increased the speed and 
simplicity of this process. Southern’s blotting method was used to clone genes and 
study gene expression, among many other DNA structural analysis applications.  
 
Dissemination of the New Technology 
 
Southern’s attempts to publish his findings were delayed. Though he invented the 
Southern blot sometime in 1973, his publication was not in print until 1975.14 His 
original submission to the Journal of Molecular Biology was rejected on the grounds 
that it was a methods paper, which the journal would only publish if it incorporated 
original and interesting results.15 To prove that he had developed a novel technique 
worthy of publication, Southern needed to conduct further experiments. 
 
 






Southern did not wait for his work to be published to spread his findings. While he 
was running experiments and gathering more data for a publication, he engaged in a 
very liberal pre-publication sharing strategy. Dissemination of the Southern blot 
started at the hands of Michael Matthews, a scientist from Cold Spring Harbor 
Laboratory, who saw Southern’s work during a visit to the Mammalian Genome Unit 
and wanted to take the technique back to the United States to use in his own work on 
viruses. Southern literally drew a schematic on a scrap of paper and gave it to 
Matthews who, “clutching this drawing,” carried Southern’s idea back with him to 
Cold Spring Harbor (see Figure 1).16 Back in the United States, Matthews and his 
colleague Mike Botchan implemented and improved upon the technique. Word about 
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this hot new blotting method began to quickly spread through the research 
community. 
 
Realizing the demand for Southern’s blotting method, the people at Cold Spring 
Harbor asked Southern if they could further disseminate the information. Southern 
agreed, requesting only that he receive acknowledgement for the origination of the 
process. Southern considers his prepublication strategy to be the reason his name 
became entwined with the technique, stating “I believe that, if it had been published in 
the normal way, it would not have had such a firm attachment.”17 When questioned 
about the prepublication sharing of information, he said “I’ve obviously no regrets 
about doing that.”18 
 
Southern’s open sharing of his method, coupled to a request for attribution, closely 
parallels the “for attribution” option of the Creative Commons licensing scheme. 
Creative Commons was founded in 2001 in part to bring a similar openness to written 
and creative works.19 The Creative Commons assists creators in choosing how their 
expressions will be licensed. The “for attribution” option is popular with academics 
and artists, as it enables others to use the material at no cost, but ensures credit for 





In 1973, Professor Southern invented the Southern blot and used an open, informal 
method of prepublication to disseminate knowledge of his technology, subject only to 
acknowledgement of its creator. In 1985, he moved from MRC to assume the Whitley 
Professorship of Biochemistry at Oxford University, and, the next year, submitted his 
first patent application. He has since received more than 90 patents in various 
jurisdictions worldwide.20 An interesting contrast to the Southern blot is the 
microarray technologies that Southern patented. Southern remained within an open, 
academic research environment throughout his career, and stayed committed to 
sharing scientific information and methods, but he now files patents for his inventions 
where he did not even consider patenting an option in the 1970s. Professor Southern’s 
story shows one man’s evolving view of the appropriate relationship among open 
science, patenting, and commercial biotechnology. Four personal and environmental 
changes have accompanied this evolution: 
• Policy affecting intellectual property (IP) 
• Attitudes about science norms 
• Southern’s role in science 
• The nature of the technologies 
 
Policy affecting IP 
 
UK policies regarding assignment of intellectual property rights for inventions using 
public funds changed in 1985. These policies reflected shifting perceptions of 
academic-industrial relations, which reflected a consensus among stakeholders—
universities, industry, and government—that academic research could enhance social 
benefit through commercialization. This reversed a post-war consensus that promoted 
nationalization of many previously privately-held companies, including transportation 
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systems and utilities.21 In 1948, Parliament passed the Development of Inventions 
Act, which set up the National Research Development Corporation (NRDC), the 
result of a long debate on how to prevent science and technology decline in Britain. 
Her Majesty’s Treasury officially granted the right of first refusal for inventions 
arising from government funding to NRDC in a Treasury Circular in 1950, TC5/50.22 
As a result, intellectual property rights to inventions created using public funds went 
to the NRDC (and later, the British Technology Group (BTG)).23 
 
The management of intellectual property from publicly-funded research changed in 
the 1980s under the Thatcher government. The Thatcher years were “marked by the 
intensification of fears that British science was in serious trouble.”24 Thatcher 
employed the same logic to remedy the ebb in British science that she often did in 
economics: roll back the state, and let market forces and enterprise dictate. On 14 
May 1985, the Thatcher government officially rescinded TC5/50 and abolished the 
BTG right of first refusal on patents.25 As a result, consumers of public research 
funds, in particular universities, were allowed to own and commercialize the 
intellectual property resulting from in-house inventions. The UK policy change, 
encouraging universities to patent inventions arising in publicly-funded research, 
paralleled the shift in US policy, specifically the Bayh-Dole statute of 1980.26 The 
Bayh-Dole statute, in turn, reflected a growing U.S. consensus that public benefit 
would be best achieved by creating incentives to patent and license inventions arising 
from public science to private firms for subsequent development into commercially 
valuable products and services.27 The change in policy happened just as commercial 
biotechnology was taking shape, as cell fusion and recombinant DNA technologies 
began to find use in drug discovery, diagnostics, agriculture, and other applications. 
 
Before being granted the right to own patents, however, a university in the UK first 
had to prove to the U.K. Research Councils that it possessed the resources and 
capabilities to manage its own intellectual property. The public Research Councils 
took different approaches to assigning intellectual property rights to universities. The 
situation was clarified after the 1999 Baker Report. In this report, John Baker 
submitted recommendations to the Minister for Science and the Financial Secretary to 
the Treasury for “increasing the rate at which their [Public Sector Research 
Establishments] research is successfully commercialized.” 28 The government 
responded by requiring Research Councils to specify the disposition of intellectual 
property at universities and other public research institutions.29 This reduced, although 
it did not entirely eliminate, variability among the Councils. 
 
With the Thatcher directive to patent and license inventions arising from government-
funded research, universities jumped at the opportunity to own intellectual property, 
including Oxford, where Southern now worked. In 1988, as a direct result of the 
Thatcher Administration changes, Oxford University formed Isis Innovation, a 
wholly-owned subsidiary designed to help the university exploit intellectual 
property.30 Intellectual property created at Oxford became generally assigned to Isis, 
which transferred the technology to industry through licensing agreements. Professor 
Southern was on the original board that helped to form Isis, thus intricately involving 
him in the academic research commercialization process at Oxford. 
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Southern’s choices concerning intellectual property and dissemination of his 
technologies shifted in concert with the UK policy changes. The Southern blot was 
invented in 1973 at a public sector research establishment (MRC Mammalian Genome 
Unit) in Edinburgh during a time when the UK endorsed government ownership of 
publicly funded research products. If patented, rights to the invention would have 
resided with government, through the NRDC; instead it was not patented at all. The 
Southern blot was created before the 1985 Thatcher changes and was not patented; the 
microarray was created after the 1985 policy changes and was patented. The policy 
change is far from the only difference, but the change of policy was one necessary 
condition for Southern, and Oxford, to patent microarray technologies. 
 
Indeed, a lack of university interest in IP pursuits is reflected in the story of the 
Southern blot. Southern does not recall being approached by his employers to patent 
the Southern blot, nor does he recall even thinking about the possibility of patenting 
his invention. Southern claims that “nobody was bothered about patents at that time,” 
but feels that if he invented the Southern blot today, he would undoubtedly have been 
approached about patenting the technique.31 Instead, Southern freely distributed 
information about how to reproduce the technique on the back of napkins and 
envelopes and through word of mouth. After a couple of years of this pre-publication 
dissemination strategy, Southern’s paper was published in the Journal of Molecular 
Biology. The way MRC handled the Southern blot suggests that either MRC did not 
actively pursue IP or that Southern was not aware that MRC was concerned about IP. 
In a professional environment not openly concerned with IP production, it is not 
surprising that Southern did not consider patenting an option, or that he was never 
approached about patenting his invention. 
 
By the time Southern filed his first patent application in 1985 and began work on 
microarray technologies in 1987, the IP policy landscape in the UK had shifted 
dramatically. Thatcher rescinded TC 5/50 in 1985, allowing universities to own and 
exploit IP, and various other UK laws and regulations had come into effect to promote 
privatization and commercialization. As a direct result of these changes, Oxford 
University established Isis Innovation, a TTO created to exploit IP resulting from 
inventions created at Oxford. Oxford now had a greater financial incentive to patent, 
and with a unit dedicated to getting and managing patents, the capacity to encourage 
employees to report patentable inventions. 
 
Southern was not a passive recipient of the effects of policy changes at Oxford, but 
was actively involved in the transformation. As a founding member of the Isis board, 
he helped to create and shape Isis Innovation. Likewise, Southern was not approached 
about patenting the microarray at Oxford. Rather, he approached Isis about patenting 
his technology. Since he was on the board of Isis, he felt that “it seemed a good idea 
to give it [Isis] something to work on.” 32 However straightforward the motivation for 
patenting the microarray, implicit in Southern’s actions was a greater knowledge and 
active acceptance of patenting scientific innovation. In the intervening years, Southern 
had learned about the possibilities and processes for pursuing IP. In submitting his 
work actively and voluntarily for patenting, Southern showed his acceptance of an 
emerging university IP exploitation system. 
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Attitude about science norms 
 
Changing policy and financial incentive may have both directly and indirectly 
influenced Southern’s decisions regarding the methods used to share his technologies, 
but Southern’s personal views on science norms—and the role that patenting plays in 
those norms—also altered. During an interview with Southern conducted last July, 
Southern was asked if he knew “anybody in the 1970s who patented a 
biotechnology,” and if so, how he felt about this person. Southern answered: 
 
‘A friend of mine, Ken Murray, patented a vaccine for Hepatitis B. 
And we thought, I mean, it was the feeling, actually, that he was a bit 
of a sell-out. But he's redeemed himself since then, because he's 
made a lot of money out of it which he used in charitable ways. So 
nobody says now that it was something he shouldn't have done. If he 
had just made himself rich and spent it on women and sports cars, I 
think we'd probably have taken a different view.’
 33 
 
Murray was working in a laboratory at MRC at the time of Southern’s invention. In 
1978, three years after the first Southern Blot article was published, Murray and Heinz 
Schaller, of the University of Heidelberg, filed applications for what became 
European patents EP0182442 and EP0013828, based on their work producing 
Hepatitis B virus antigens.34 Murray and Schaller assigned their Hepatitis B patent 
rights to Biogen, a biotechnology startup company that Murray had helped co-found 
that same year with future Nobel Laureates Walter Gilbert, Philip Sharp, and other 
molecular biology luminaries. Murray’s patent on the Hepatitis B antigen was one of 
the first patents of its kind in the UK. 
 
Southern’s characterization of the Murray Hepatitis patent is interesting. He was 
specifically asked about how he felt about a scientist who patented a biotechnology, 
but Southern answered in the plural we. Southern framed his response as the 
collective perception of a larger scientific community when queried about his own 
opinions about biotech patenting, and specifically about his friend Kenneth Murray. 
Southern’s statement also shows how Kenneth Murray was retroactively redeemed by 
how he used the profits gained from the IP in “charitable ways.” Importantly, when 
recalling how he felt in the 1970s about patenting, Southern tells a tale of negative 
judgment. Implicit in Southern’s statement is that his concept of scientific norms in 
the 1970s did not include patenting. 
 
Contrast how Southern describes himself in the 1970s with how he speaks today about 
biotechnology IP. Southern now thinks explicitly and at length about IP strategies and 
about when to patent and when to publish and when to do both. He is an adept 
businessman as well as scientist, and he expresses mastery of the technical language 
in both arenas. Southern did express judgment about biotech IP, but did not use 
language about morality to discuss his qualms. For instance, he stated that he wished 
“weak, defensive patents” were not so pervasive as they are really “a killer,” but he 
did not lament over the immorality of biotech patenting per se.35 IP has incorporated 
itself into Southern’s conception of science norms. Open sharing is no longer 
necessarily free dissemination of an unpatented technology, but now also includes 
liberal and feasible licensing procedures designed to make a technology as widely 
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available as possible. IP is as routine and expected in scientific research as, well, the 
Southern blot. 
 
Edwin Southern in the 1970s felt very differently about the relationship between 
science norms and IP than he does today. What changed his opinions? When did his 
views about IP change? Here, Southern recounts his experience (and that of the 
science community at large) in the 1980s as shifting away from science norm ideals 
that exclude IP towards a forced acceptance of IP by research institutions: 
 
‘I think gradually I became under pressure. We all had to, we were 
under contract actually, to tell our funding agencies of any 
inventions which were patentable, anything in our work that could 
be commercialized. And at first, we were very resistant to that 
attitude. We thought that this would do the things you've been 
hinting at, you know, inhibit the spread of ideas and materials and 
so on. And so there was a resistance to that initially. When did that 
change? I think by mid-80's it was beginning to change. People were 
beginning to accept the idea that we had to do it, and that eventually 
became a sort of matter of course. I don't know anybody now who 
would put up a really strong resistance to that idea. They may not 
like it, but they would conform.’
 36 
 
From this statement, and from Southern’s decisions about intellectual property, it is 
clear that a shift in Southern’s thinking about the role of patents in academic research 
changed between 1973 and 1985. 
 
Southern’s role in science 
 
“We are pleased that the English courts have agreed to decide this issue as a 
preliminary issue, and believe that they will declare invalid Affymetrix's attempts to 
secure a license by means other than negotiation with OGT.”37 In this Oxford Gene 
Technology (OGT) press release, Professor Southern sounds more like an IP lawyer 
or a business shark than he sounds like a scientist. As Southern entered into the world 
of science and IP interactions and became invested in these interactions both 
personally and financially via OGT, he acquired several roles. In the 1970s, Southern 
was primarily a scientist, and also a colleague, friend, lab group manager, etc. Today, 
Southern is all these things, but he must also be an amateur lawyer and businessman. 
One of the key changing components in Southern’s story is his personal migration 
towards becoming an industry-savvy scientist, as opposed to a scientist who practices 
only pure science. 
 
Nature of technologies 
 
In addition to Southern changing views on patenting since the 1970s, the technologies 
in question—the Southern blot and the microarray—are very different in terms of 
both complexity and marketing potential. One reason the Southern blot is widely used 
as a molecular biology procedure is that it is easily reproduced with materials 
laboratories have at hand. All a Southern blot requires is a “paper towel and a baking 
tray and some salt solution.”38 But the Southern blot’s simplicity also renders it 
difficult to package as a profit-making product or service. A prepackaged and more 
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costly Southern blot kit is a hard sell if potential buyers can build the product 
themselves much cheaper and without great effort. 
 
Microarray technologies, in contrast, require extensive instrumentation, and their use 
entails detection methods and interpretation software. Meanwhile, integrating the 
components entails substantial engineering, and final products and services involve 
substantial investments and the kind of engineering work that universities are unlikely 
to undertake beyond the prototype stage. Moreover, economies of scale in production 
are apparent, as is the need for quality control, making dedicated manufacture and sale 
by private firms an efficient mechanism to produce them. Unlike the Southern blot 
which requires only commonly used materials, the microarray consists of small, clean 
chips spotted with thousands of oligonucleotide strands that must be synthesized. For 
a laboratory to produce its own microarray chips, the lab must have expensive 
equipment and expert staff, and must use many microarray chips for the equipment 
expenditure to be cost effective. Small laboratory outfits may not have the resources 
to produce their own microarray chips, and if it were not for microarray chip 
production companies, might be excluded from research that utilizes microarrays. 
Southern believes: 
 
‘In the case of microarrays, to do it properly you have to 
commercialize it. I think the "home-brew" business of microarrays 
sort of works alright, but it's clear by now, I think, that the 
commercial flavors of microarrays are superior to the home-brew 
flavors. You might find people that would argue with that, but I 
think… I'm sure that's really true.’ 39 
 
As microarray chips are difficult and costly to produce, there is more of a potential for 
a microarray market than there is for a Southern blot market. Furthermore, a patent on 
microarray technologies is likely to be more profitable than a patent on the Southern 
blot would have been. One factor influencing the degree of profitability for these 
patents is the ability to enforce the patents via legal action. Because Southern blots are 
easily replicated, bringing litigation against infringing uses of Southern blot patents 
would be difficult. Microarray patents have the potential for being easier to enforce, 
since the skill and money required to produce microarrays would eliminate the 
possibility of every small lab outfit producing their own. Moreover, patents can be 
licensed to manufacturers, rather than enforced against individual researchers using a 
simple laboratory method. Legal action concerning microarrays can be directed at 
larger lab groups and companies, making litigation procedures practical and 
potentially effective. 
 
Deciding what to do with a technology—whether to patent or publish, or both—
requires sophistication in balancing science and business. It is important to be able to 
judge the cost and benefits of patenting, versus more liberal dissemination methods 
through publication or free, open sharing. Although one might apply for many patents, 
very few of those patents will “actually [pay] off.” Southern reasons: 
 
‘It's a startling statistic, the costs of filing a patent are quite high as 
you undoubtedly know. You've got to pay your lawyers, in Europe 
you've got to pay - to maintain the thing - you've got to pay 
translation costs, so the total cost of taking a patent through to point 
where it is really useful is about £20,000 to £50,000. You can almost 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.2, pp.50-61 
 
_____________  59 
 
Genomics, Society and Policy, Vol.2 No.2 (2006) ISSN: 1746-5354 
double that for dollars… That's serious money. To earn that sort of 
money, let's suppose it's something that could bring in a 10 percent 
royalty… To justify a 100,000 dollar investment in the filing of the 
patent, it's got to be a million dollar invention. Just to break even. To 
make anybody any money, it's got to be a 10 million dollar invention. 




The contrast between the profitability of the Southern blot and the microarray 
exemplifies one potential cause of the rise in biotechnology patenting in recent years. 
As Walsh and Cohen note, “the revolution in molecular biology, combinatorial 
chemistry, bioinformatics and related fields… has spawned discoveries of enormous 
commercial value since the 1970s.”41 Higher commercial value, increasingly complex 
technology, and need for greater development investment have all contributed to more 





Professor Sir Edwin Southern’s story shows the fruitful career of one man in a rapidly 
changing social and scientific environment. Southern is the father of several 
successful inventions, including the Southern blot and some seminal patents in 
microarray technologies. Southern invented the Southern blot in 1973 and used an 
informal method of prepublication to disseminate knowledge of his technology until it 
was published in the Journal of Molecular Biology in 1975. A decade after the 
Southern blot, in 1985, Southern left the MRC Mammalian Genome Unit in 
Edinburgh to become the head of the biochemistry department at Oxford. That same 
year, UK Prime Minister Margaret Thatcher implemented policy changes that allowed 
universities to more easily exploit IP resulting from publicly funded research, 
analogous to the U.S. Bayh-Dole Act. In 1988, Southern invented a microarray 
technology and filed a patent on what he created. 
 
Four changes help explain Southern’s shift from not patenting the Southern Blot to 
patenting microarray technologies: UK policy affecting IP; attitudes about patenting 
among scientists, industry, and government; Southern’s role in science; and the 
increasing complexity and need for development investment in the technologies. The 
cause-effect relationship between these is complicated and nonlinear, but it is clear 
that the components changed in parallel between 1973 and 1988. Not patenting the 
Southern blot in 1973 was not a conscious policy decision, but patenting microarray 
technologies in the 1980s followed from the increased involvement of private firms in 
molecular biology, growing acceptance of intellectual property as a result of academic 
research, increased attention to commercializing such intellectual property to produce 
social benefits, and increased sophistication about intellectual property among 
scientists. Edwin Southern’s career spans this period of change, exemplified by two 
seminal technologies that he contributed: the Southern Blot and microarray 
technologies.  
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